CVS break-up underscores limits of M&A-led healthcare strategy

Traders Union
All News
Business & Wealth
Companies
CVS break-up limits healthcare strategy

Highlights

CVS will separate its retail pharmacy unit from its $320 billion health insurance business, highlighting the challenges of its $150 billion M&A-led strategy.
Adding to operational pressures, both CVS divisions report operating margins below 5 percent amid growing regulatory calls to separate drugstores and pharmacy benefit managers.
CVS's market capitalisation dropped by nearly $15 billion after the break-up announcement, with investors skeptical that the split will improve future prospects.

Break-up follows years of dealmaking

As reported by Financial Times, CVS announced last week that it is separating its retail pharmacy unit from its health insurance business, which the company estimates will generate $320 billion in revenue this year and is about twice the size of the retail arm.

The separation points to the limits of a strategy built around acquisitions. Over two decades, CVS completed nearly $150 billion of deals, including Caremark, Aetna and Oak Street Health, in an effort to control more of the patient value chain and combine drug retailing, benefits management and insurance under one group.

CVS had argued that the model would improve customer outcomes and deliver significant financial gains, including $1.7 billion of cost and revenue synergies from Caremark and $500 million from Oak Street. Yet its shares have risen only about 30 per cent over the past decade, while the S&P 500 Healthcare index has more than doubled.

Regulatory and market pressures remain

The company also faces a tougher external environment as policymakers and regulators push back against the influence of large healthcare intermediaries. U.S. states and competition authorities are showing greater interest in separating drugstores from pharmacy benefit managers that oversee how medicines reach patients.

That pressure comes as both sides of CVS's business operate on thin margins. Retail pharmacy and health insurance are both high-volume, low-margin activities, with each half of CVS posting operating margins below 5 per cent.

Broader sector conditions are also shifting. U.S. healthcare spending has grown faster than GDP for decades and has trended toward 20 per cent of annual economic output, but efforts since 2020 to slow cost growth are having an effect, while shares in UnitedHealth Group, the largest U.S. payer, have fallen by a third in the past 18 months.

Investors do not appear convinced that the split alone will improve CVS's prospects. The company's market capitalisation fell by nearly $15 billion on Wednesday, and Democratic Senator Elizabeth Warren said on social media on Thursday that CVS is still trying to "rip people off".

Earlier, we reported that the S&P 500 fell 1.01% as rising Treasury yields pressured most sectors despite a tech rebound.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.